New pill aims to keep hearts in rhythm and stop AFib relapse
NCT ID NCT06540352
First seen Apr 29, 2026 · Last updated May 05, 2026 · Updated 1 time
Summary
This study tests a new drug called Refralon in 175 adults with persistent atrial fibrillation or flutter. After doctors restore normal heart rhythm, participants take either a low or high dose of Refralon or a placebo daily for 6 months. The goal is to see if the drug can prevent the heart rhythm problem from returning and to find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Organization
Moscow, Russia
Conditions
Explore the condition pages connected to this study.